Toggle navigation
Login
Toggle navigation
JavaScript is disabled for your browser. Some features of this site may not work without it.
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
QMRO Home
Blizard Institute
Centre for Neuroscience, Surgery and Trauma
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
QMRO Home
Blizard Institute
Centre for Neuroscience, Surgery and Trauma
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Browse
All of QMRO
Communities & Collections
By Issue Date
Authors
Titles
Subjects
This Collection
By Issue Date
Authors
Titles
Subjects
Administrators only
Login
Statistics
Most Popular Items
Statistics by Country
Most Popular Authors
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
View/
Open
Published version (292.1Kb)
Volume
376
Pagination
209 - 220
DOI
10.1056/NEJMoa1606468
Journal
NEW ENGLAND JOURNAL OF MEDICINE
Issue
3
ISSN
0028-4793
Metadata
Show full item record
Authors
Montalban, X; Hauser, SL; Kappos, L; Arnold, DL; Bar-Or, A; Comi, G; de Seze, J; Giovannoni, G; Hartung, H-P; Hemmer, B
URI
http://qmro.qmul.ac.uk/xmlui/handle/123456789/18928
Collections
Centre for Neuroscience, Surgery and Trauma
[1147]
Licence information
From New England Journal of Medicine, Montalban X, et al., Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis, 376:209-220. DOI: 10.1056/NEJMoa1606468. Copyright © 2016 Massachusetts Medical Society. Reprinted with permission.
Copyright statements
Copyright © 2016 Massachusetts Medical Society. All rights reserved.